427 related articles for article (PubMed ID: 16955982)
41. Current and emerging pharmacological treatment options for dementia.
Ringman JM; Cummings JL
Behav Neurol; 2006; 17(1):5-16. PubMed ID: 16720956
[TBL] [Abstract][Full Text] [Related]
42. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
Sevilla C; Jiménez Caballero PE; Alfonso V; González-Adalid M
Dement Geriatr Cogn Disord; 2009; 28(3):196-205. PubMed ID: 19738386
[TBL] [Abstract][Full Text] [Related]
43. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
44. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Grossberg GT; Edwards KR; Zhao Q
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
[TBL] [Abstract][Full Text] [Related]
45. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration.
Kurz A; Van Baelen B
Dement Geriatr Cogn Disord; 2004; 18(2):217-26. PubMed ID: 15237280
[TBL] [Abstract][Full Text] [Related]
46. Noncognitive symptoms and long-term treatment expectations for Alzheimer disease.
Blesa R
Alzheimer Dis Assoc Disord; 2004; 18 Suppl 1():S9-16. PubMed ID: 15249843
[TBL] [Abstract][Full Text] [Related]
47. [Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].
Kohler J; Riepe MW; Jendroska K; Pilartz H; Adler G; Berger FM; Calabrese P; Frölich L; Gertz HJ; Hampel H; Haupt M; Mielke R; Paulus HJ; Zedlick D
Fortschr Med Orig; 2002 Dec; 120(4):135-41. PubMed ID: 12613271
[TBL] [Abstract][Full Text] [Related]
48. Maintaining functional and behavioral abilities in Alzheimer disease.
Winblad B
Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S34-40. PubMed ID: 11669508
[TBL] [Abstract][Full Text] [Related]
49. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
Harry RD; Zakzanis KK
Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322
[TBL] [Abstract][Full Text] [Related]
50. Treatment of Alzheimer's disease in the long-term-care setting.
Smith DA
Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
[TBL] [Abstract][Full Text] [Related]
51. Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease.
Formiga F; Fort I; Robles MJ; Rodriguez D; Regalado P
Dement Geriatr Cogn Disord; 2010; 29(3):198-203. PubMed ID: 20332637
[TBL] [Abstract][Full Text] [Related]
52. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil and galantamine.
Capellà D; Vidal X
Age Ageing; 2007 Mar; 36(2):234; author reply 235. PubMed ID: 17255086
[No Abstract] [Full Text] [Related]
53. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Aguglia E; Onor ML; Saina M; Maso E
Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
[TBL] [Abstract][Full Text] [Related]
54. Editorial comment--How to treat vascular dementia?
Bonelli RM
Stroke; 2003 Oct; 34(10):2331-2. PubMed ID: 14500926
[No Abstract] [Full Text] [Related]
55. [Variability and trends in dementia drug consumption in Castile-La Mancha (Spain). Estimated prevalence of Alzheimer's disease].
Criado-Alvarez JJ; Romo Barrientos C
Neurologia; 2010 May; 25(4):234-8. PubMed ID: 20609301
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.
Raina P; Santaguida P; Ismaila A; Patterson C; Cowan D; Levine M; Booker L; Oremus M
Ann Intern Med; 2008 Mar; 148(5):379-97. PubMed ID: 18316756
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Hansen RA; Gartlehner G; Webb AP; Morgan LC; Moore CG; Jonas DE
Clin Interv Aging; 2008; 3(2):211-25. PubMed ID: 18686744
[TBL] [Abstract][Full Text] [Related]
58. A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
Alisky JM
J Alzheimers Dis; 2003 Dec; 5(6):477-8. PubMed ID: 14757938
[No Abstract] [Full Text] [Related]
59. Drugs for cognitive loss and dementia.
Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
[TBL] [Abstract][Full Text] [Related]
60. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
Lampela P; Tolppanen AM; Tanskanen A; Tiihonen J; Lavikainen P; Hartikainen S; Taipale H
Ann Med; 2017 May; 49(3):230-239. PubMed ID: 27786552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
